Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer  by Zhao, Ran et al.
EBioMedicine 8 (2016) 30–39
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comImplications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a)
in CancerRan Zhao a, Bu Young Choi b, Mee-Hyun Lee a,⁎, Ann M. Bode c, Zigang Dong a,c,⁎⁎
a China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, Henan 450008, China
b Department of Pharmaceutical Science and Engineering, Seowon University, Cheongju 361-742, South Korea
c The Hormel Institute, University of Minnesota, Austin, MN 55912, USA⁎ Correspondence to: M.-H. Lee, China-US (Henan) Hor
⁎⁎ Correspondence to: Z. Dong. The Hormel Institute, Un
E-mail addresses:mhlee@hci-cn.org (M.-H. Lee), zgdo
http://dx.doi.org/10.1016/j.ebiom.2016.04.017
2352-3964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 10 February 2016
Received in revised form 1 April 2016
Accepted 14 April 2016
Available online 3 May 2016Aberrant gene silencing is highly associatedwith altered cell cycle regulation during carcinogenesis. In particular,
silencing of the CDKN2A tumor suppressor gene, which encodes the p16INK4a protein, has a causal link with sev-
eral different types of cancers. The p16INK4a protein plays an executional role in cell cycle and senescence through
the regulation of the cyclin-dependent kinase (CDK) 4/6 and cyclin D complexes. Several genetic and epigenetic
aberrations of CDKN2A lead to enhanced tumorigenesis andmetastasis with recurrence of cancer and poor prog-
nosis. In these cases, the restoration of genetic and epigenetic reactivation of CDKN2A is a practical approach for
the prevention and therapy of cancer. This review highlights the genetic status of CDKN2A as a prognostic and
predictive biomarker in various cancers.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
CDKN2A
p16INK4a
Genetic alterations
Epigenetic alterations
CancerContents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2. Genetic alterations of CDKN2A in various cancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.1. Lymphoma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.2. Skin cancer and melanoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.3. Head and neck cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.4. Pancreatic cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.5. Lung cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.6. Esophageal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.7. Gastric cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.8. Colorectal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.9. Ovarian cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.10. Prostate cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.11. Renal cell carcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3. Molecular switches associated with p16INK4a aberrations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4. Epigenetic induction of CDKN2A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.1. Induction of CDKN2A by regulatory genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.2. Induction of p16INK4a by reagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Outstanding questions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Search strategy and selection criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Financial support. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Disclosure of potential conﬂicts of interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Authors' contribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37mel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, Henan 450008, China.
iversity of Minnesota, 801 16th Ave NE, Austin MN55912, USA.
ng@hi.umn.edu (Z. Dong).
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
31R. Zhao et al. / EBioMedicine 8 (2016) 30–39Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381. Introduction
Cancer comprises a collection of complex genetic and epigenetic dis-
eases that arise through multistep processes (Tallen and Riabowol,
2014). Tumor cells acquire common properties, including unlimited
proliferation potential, self-sufﬁciency in growth signaling, neovascu-
larization for nutrient and oxygen supply, and resistance to anti-prolif-
erative and apoptotic stimuli (Hanahan and Weinberg, 2011). In
resting cells, the cell cycle is strictly managed by a set of regulatory pro-
teins that control the various cell cycle checkpoints (Collado et al., 2007;
Collins et al., 1997). This cell cycle machinery is often deregulated in
cancer as a consequence of the silencing of various tumor suppressor
genes (Collins et al., 1997; Tallen and Riabowol, 2014). In fact, loss of
tumor suppressor genes and their encoded proteins through deletion,
inactivating mutations, epigenetic silencing or post-translational modi-
ﬁcation results in tumorigenesis. The progression of themammalian cell
cycle fromG1 tomitosis is regulated by various cyclin proteins and their
catalytic subunits referred to as cyclin-dependent kinases (CDKs)
(Nabel, 2002). A family of cyclin–CDK inhibitor proteins (CDIs), which
bind and inactivate the CDKs, has been isolated. This family includes
the p16INK4a, p21CIP1, p27KIP1, and associated proteins p15INK4b,
p18INK4c, p19INK4d and p57KIP2 (Nabel, 2002). These proteins potentially
act as tumor suppressors and their inactivation corresponds with
human carcinogenesis.
One of the tumor suppressor proteins that is inactivated in cancer is
thep16INK4a protein,which is encoded by the cyclin-dependent kinase in-
hibitor 2A (CDKN2A) ormultiple tumor suppressor 1 (MTS1) gene (Fig. 1)
(Witcher and Emerson, 2009). The CDKN2A gene is located within the
frequently deleted chromosomal region 9 of p21 (Gil and Peters,
2006). This gene (8.5 kb full length) contains two introns and three
exons and encodes the p16INK4a protein. The p16INK4a protein is a pro-
tein consisting of 156 amino acids with a molecular weight of 16 kDa
and is a negative regulator of the cell cycle (Serrano et al., 1993). In
addition to p16INK4a, CDKN2A encodes a completely unrelated tumorFig. 1. Schematic structure of the INK4a/ARF locus and the role of p16INK4a in cells.CDKN2A is pro
CDK4/6 complexes and inhibits the activation of the transcription factor, E2F1, which inducessuppressor protein, alternate open reading frame (ARF or p19Arf in
mice), which interacts with the p53 regulatory protein, mouse double
minute 2 homolog (MDM2) (Pomerantz et al., 1998). The simple
tandem arrangement is complicated by the presence of an additional
exon 1β, which is transcribed from its own promoter. The resulting
RNA incorporates exons 2 and 3, but speciﬁes a distinct protein because
the exons are translated by an alternative reading frame. Thus, while
exons 2 and 3 are shared by the twomRNAs, they encode different pro-
tein products, p16INK4a and ARF (Quelle et al., 1995). The speciﬁc bind-
ing of the p16INK4a protein to CDK4 or CDK6 induces an allosteric
conformational change in these proteins and inhibits the formation of
the complex between CDK4 or 6 and cyclin D (Serrano et al., 1993).
The lack of this complex formation maintains the retinoblastoma pro-
tein (Rb) in its hypo-phosphorylated and growth-suppressive states.
This leads to the induction of G1 phase cell cycle arrest through the for-
mation of the Rb/E2Fs-repressive complex (Fig. 1) (Weinberg, 1995).
The loss of p16INK4a is increasingly common with advancing stages of
various neoplasms, suggesting that p16INK4a inactivation may contrib-
ute to cancer progression. The frequent inactivation of p16INK4a induced
by homozygous deletion or promoter hyper-methylation and pointmu-
tation has been observed in various cancers (Table 1).
Epigenetic alterations are suggested to regulate gene expression
without affecting the base sequence. Thesemodiﬁcations include geno-
mic DNA-methylation, histone modiﬁcations, chromatin remodeling
and miRNA/non-coding RNA-induced regulation of gene expression
(Hauptman and Glavac, 2013; Portela and Esteller, 2010; Sarkar et al.,
2015). The polycomb group (PcG) genes, ﬁrst identiﬁed in Drosophila
melanogaster, encode the highly conserved PcG proteins, which form
two large macromolecular complexes classiﬁed as polycomb repressive
complex-1 (PRC1) and -2 (PRC2). The PRC1 complex consists of B lym-
phoma Mo-MLV insertion region 1 homolog (BMI1), mPh1/2, Pc/
chromobox (CBX) and RING1A/B, and sustains silencing of chromatin.
The mammalian PRC1 might harbor speciﬁcity against selecting one of
the multiple Pc/CBX homologs. The PRC2 complex is composed ofducedby alternative splicing of E1, E2 and E3. The p16INK4a protein binds to the cyclinD and
proteins to move from the G1 phase to S phase in the cell cycle.
Table 1
Changes of CDKN2A in various cancers.
Cancer types Status of alteration Frequency (%) Reference
Gastric lymphoma Promoter hyper-methylation 29.7% (11/37) Huang et al. (2007)
Burkitt's lymphoma Promoter hyper-methylation 72.5% (37/51) Robaina et al. (2015)
Skin cancer Promoter hyper-methylation, histone modiﬁcation 50–70%, 80–90% Chen et al. (2012a)
Melanoma
Promoter hyper-methylation 25.9% (15/58) Kostaki et al. (2014)
Histone modiﬁcation Sarkar et al. (2015)
Promoter hyper-methylation, non-synonymous mutation 25% (15/59), 16% (9/56) Jonsson et al. (2010)
Head and neck squamous cell
carcinoma
Mutation/promoter hyper-methylation 57% (138/243) Chung et al. (2015)
Promoter hyper-methylation 54.5% (6/11 cell line) and 66.7% (20/30) El-Naggar et al. (1997)
Oral cancer Promoter hyper-methylation 60% (6/10) Asokan et al. (2014)
Pancreatic adenocarcinoma
Mutation 11.8% (2/17)
Salo-Mullen et al.
(2015)
Promoter hyper-methylation 24.6% (14/57) Jiao et al. (2007)
Non-small cell Lung cancer (NSCLC)
Homozygous deletion (HD)/mutation/promoter
hyper-methylation
53%/13%/33% in cell lines Tam et al. (2013)
Mutation/frameshift/HD 19% (12/63) Marchetti et al. (1997)
Esophageal squamous cell carcinoma
Loss of heterozygocity (LOH)/mutation 13% (5/38)/6% (4/67) Kuwabara et al. (2011)
Promoter hyper-methylation 81.7% (210/257) Chen et al. (2012b)
Deletion 20% (22/106) Qureshi et al. (2012)
Gastric cancer Hyper-methylation
81.6% (40/49, EBVaGC), 33.3% (15/45,
EBVnGC)
He et al. (2015)
Colorectal cancer
Promoter hyper-methylation 11.9% (34/285) Kim et al. (2010)
Promoter hyper-methylation 17.1% (87/497) Rajendran et al. (2015)
Epithelial ovarian caricnoma Promoter hyper-methylation 43% (58/134) Bhagat et al. (2014)
Prostate cancer
Expression of ANRIL, CBX7, and EZH2 Yap et al. (2010)
Promoter hyper-methylation 47.6% (10/21) Ameri et al. (2011)
32 R. Zhao et al. / EBioMedicine 8 (2016) 30–39embryonic ectoderm development (EED), suppressor of zeste (SUZ)12
and enhancer of zeste homolog (EZH)1/2, and initiates repression of tar-
get genes by di- and trimethylation of lysine 27 of histone H3
(H3K27me2 and H3K27me3) (Bracken et al., 2007; Cao et al., 2002).
Thus, activation of PRC1 and PRC2 induces gene silencing through
histone modiﬁcation ultimately affecting the chromatin structures.
Long non-coding RNAs are transcripts longer than 200 nucleotides
and lack protein-coding capacity. These RNAs might play a major role
in programming the epigenome by cooperating and coordinating with
the PcG complexes to impose chromatin states in a dynamic mannerFig. 2. Frequency of CDKN2A alterations in various cancer types. Based on the type(Aguilo et al., 2011). The purpose of this mini-review is to shed light
on the molecular mechanisms of genetic and epigenetic changes in
p16INK4a and the implications in carcinogenesis.2. Genetic alterations of CDKN2A in various cancers
The changes in CDKN2A/p16INK4a status are highly variable depend-
ing on the type of cancer. The following section describes the mecha-
nisms of p16INK4a inactivation in various cancers (Table 1; Fig. 2).s of aberrant CDKN2A, the bars represent the percentage of changes reported.
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Several studies have demonstrated that promoter hyper-methyla-
tion leads to the loss of p16INK4a expression in lymphoma. Gastric lym-
phoma is an extra-nodal non-Hodgkin's lymphoma and is associated
with 2–8% of all gastric cancers (Alevizos et al., 2012). Huang et al. re-
ported that 26.5% (13 of 49) of primary gastric lymphomas exhibited
hyper-methylation of theCDKN2Apromoter, suggesting that expression
of p16INK4a is a clinical risk factor for gastric lymphoma (Huang et al.,
2007). Burkitt's lymphoma is a common subtype of B-cell non-
Hodgkin's lymphoma in children and adolescents (Molyneux et al.,
2012). A recent analysis of 51 Burkitt's lymphoma tumor samples re-
vealed that methylation of the CDKN2A promoter occurred in 72.5% of
the samples and nuclear expression of the p16INK4a protein remained
undetectable in about 41% of the samples (Robaina et al., 2015). In
this study, CDKN2A promoter methylation was detected in 32 patient
samples (80%) at stage III/IV of the cancer (Robaina et al., 2015).
2.2. Skin cancer and melanoma
Solar ultraviolet (UV) radiation is the most common risk factor for
the initiation and promotion of melanoma and non-melanoma skin car-
cinogenesis (de Gruijl, 1999). The CDKN2A gene is a melanoma suscep-
tibility gene and its mutations are present in 20 to 40% of familial and 2
to 3% of sporadic melanomas (Kostaki et al., 2014). The inactivation of
CDKN2A in skin cancer involves histone modiﬁcations as well as DNA
methylation. Chronic exposure of HaCaT skin keratinocytes to UVA radi-
ation has been reported to cause 80 to 90% histone methylation
(H3K4m3) and 50 to 70%DNAmethylation in the CDKN2A promoter re-
gion (Chen et al., 2012a). Deletion of p16INK4a has also been detected in
50% of melanomas and its inactivation by point mutations occurs in
about 9% of cases, which correlates with an increased risk of metastases
and disease progression. Methylation of the CDKN2A gene promoter oc-
curs in about 5 to 19% of sporadicmelanomas, whereas promotermeth-
ylation of the gene was found in 27 to 33% of melanoma metastases
(Kostaki et al., 2014). In cutaneous melanoma metastases, the CDKN2A
promoter is hyper-methylated in about 25% (15/59) of cases and non-
synonymous mutation of the gene was observed in about 16% (9/56)
of cases examined (Jonsson et al., 2010).
ANRIL (antisense noncoding RNA in the INK4 locus) mediates a cis-
acting silencingmechanism. ANRIL binds with PRC1 at the RNA-binding
domains of CBX7 and methylates the CDKN2A promoter region at
H3K27, which inhibits CDKN2A gene expression (Sarkar et al., 2015;
Yap et al., 2010; Sato et al., 2010).
2.3. Head and neck cancer
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous
disease that arises in the areas of the nasal and oral cavities, pharynx and
larynx. Although HNSCC can be caused by infection with human papillo-
ma virus (HPV) (Bishop et al., 2013), approximately 90% of HPV-negative
HNSCC tumors exhibit low expression of CDKN2A. This is largely due to
mutations, loss of heterozygosity, and DNA hyper-methylation of the
gene (Veganzones et al., 2015). In one study, 57% of HPV-negative
HNSCC from the TCGA (The Cancer Genome Atlas) dataset was due to
mutation or loss of the CDKN2A gene (Chung et al., 2015). In primary
HNSCCwith deﬁcient expression of CDKN2A, 66.7% (20/30) of the tumors
exhibited DNA methylation of the CDKN2A promoter. The number of
methylations was found to be 4 methylations at exon 1, 7 at exon 2 and
9 each at exons 1 and 2 (El-Naggar et al., 1997).
Oral cancer includes a group of neoplasms affecting any region of the
oral cavity, pharyngeal regions and salivary glands. More than 90% of all
oral neoplasms are oral squamous cell carcinomas (OSCCs)
(Markopoulos, 2012). Genetic alterations in OSCC might activate muta-
tions or methylation of cell cycle regulatory genes, thereby promoting
cell survival and proliferation (Al-Kaabi et al., 2014). In OSCC patients,hyper-methylation of the CDKN2A promoter was observed 60% of the
time and oral leukoplakia patients also exhibited 60% hyper-methylation
in the CDKN2A promoter (Asokan et al., 2014).
2.4. Pancreatic cancer
Because of their severemetastatic potential, pancreatic tumors are the
most aggressive types of cancer. Expression of CDKN2A has been reported
to be aberrant in ~95%of pancreatic adenocarcinomas, and approximately
15%of those (El-Naggar et al., 1997) and24.6% in another study (Jiao et al.,
2007)were attributed to promoter hyper-methylation. The CDKN2A gene
is abnormally methylated in 27% of pancreatic cancer cell lines (Moore et
al., 2001). In addition, themutation of CDKN2A occurred 11.8% of the time
in hereditary pancreatic cancer patients (Salo-Mullen et al., 2015).
2.5. Lung cancer
Lung cancer is the leading cause of cancer death and most patients
with lung cancer suffer from non-small cell lung cancer (NSCLC)
(Siegel et al., 2015). Alterations in CDKN2Awere examined in 63NSCLCs
samples of which 30 samples were primary resected NSCLCs with met-
astatic involvement of thoracic lymph nodes and 33 NSCLCs were with-
out lymph node metastases (Marchetti et al., 1997). The analysis
revealed that 6 NSCLC tumor samples had somatic aberrations of the
CDKN2A gene, including 4 mutations, 1 frame-shift and 1 homozygous
deletion (Marchetti et al., 1997). These alterations of CDKN2Awere sig-
niﬁcantly associated with lymph node metastasis of NSCLC. Further
analysis of 40 NSCLC adenocarcinoma cell lines revealed that CDKN2A
was inactivated in 75% (30/40) of cases including 16 homozygous dele-
tions, 10 methylations and 4 mutations (Tam et al., 2013). In another
study, alteration of CDKN2A in NSCLC adenocarcinoma tissue samples
was noted as 38% (17/45) and included 10 homozygous deletions, 4
methylations and 3 mutations (Tam et al., 2013).
2.6. Esophageal cancer
Esophageal cancer is the 6th leading cause of cancer death worldwide
(Zhang, 2013). Esophageal squamous cell carcinoma (ESCC) ismore com-
mon in the developingworld and arises from the epithelial cells. The pro-
moter region of CDKN2A was highly methylated in tissue samples from
Chinese subjects (81.7% or 210/257) (Chen et al., 2012b). Among 38 Jap-
anese ESCC samples examined, 13% showed a loss of heterozygosity of the
CDKN2A gene and 67 tumors showed 6% with CDKN2A mutations
(Kuwabara et al., 2011). A novel 7 base pair (TCCAGCC) deletion in 22
of 106 (~20%) esophageal tumor samples was observed in exon 2 of
CDKN2A (Qureshi et al., 2012). An in silico study revealed that the deletion
of these 7 base pairs resulted in premature termination and caused insta-
bility of the p16INK4a/CDK6 complex (Qureshi et al., 2012).
2.7. Gastric cancer
Gastric (stomach) cancer develops in the lining of the stomach. In a
meta-analysis of Chinese gastric cancer patients, hyper-methylation of
the CDKN2A promoter was recorded as 43.3% of the median average
(28.3–64.4%), and was signiﬁcantly correlated with CDKN2A promoter
methylation and carcinogenesis (Peng et al., 2014;Wang et al., 2014). In-
fectionwith the Epstein-Barr virus (EBV) is one risk factor for gastric can-
cer. EBV-associated gastric carcinoma (EBVaGC) accounts for
approximately 8–10% of all gastric carcinomas (Liang et al., 2014).
Hyper-methylation of the CDKN2A promoter was detected in 81.6% and
33.3% of the EBVaGC and EBVnGC (EBV-negative gastric carcinomas), re-
spectively (He et al., 2015). These ﬁndings suggest that a high level of
CDKN2A promoter methylation is a risk factor for developing EBV-associ-
ated gastric cancers. Another important etiologic factor for gastric carcino-
genesis is Helicobacter pylori (H. pylori) infection. Matsusaka et al.
demonstrated thatH. Pylori infection promotes CDKN2ADNAmethylation
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creased lymph nodemetastasis, and lower survival rates of gastric cancer
patients (Matsusaka et al., 2014; Qu et al., 2013).
2.8. Colorectal cancer
The development of colorectal cancer involves genetic and epigenetic
changes of several tumor suppressor genes, including CDKN2A (Chan et
al., 2002). Similar to other cancers, the CDKN2A gene is silenced through
promoter hyper-methylation during the course of colorectal cancer path-
ogenesis (Kim et al., 2010). Kim et al. reported that promotermethylation
of CDKN2A occurred in 11.9% of 285 sporadic colorectal cancer patients.
Among theseCDKN2Ahyper-methylated cancer patients, 10.6% of 264pa-
tients exhibited microsatellites with low frequency, whereas 28.6% of 21
patients showed microsatellites with high frequency (Kim et al., 2010).
In another study, CDKN2A promoter methylation occurred in 17.1% of
497 patients and its regulation was highly associated with poor survival
in stage II and III colorectal cancer patients treated with adjuvant
ﬂuoropyrimidine (Lee et al., 2015). The prognostic value of concurrent
methylation of the CDKN2A promoter was associated with gender varia-
tion and was signiﬁcant only in male patients (Lee et al., 2015).
2.9. Ovarian cancer
Ovarian cancer is the most common form of gynecological cancer
and a leading cause of cancer-related mortality among women (Jayson
et al., 2014). This cancer is diagnosed usually at an advanced stage and
has a high rate of recurrence (Hennessy et al., 2009). In a recent study,
Bhagat et al. demonstrated that the frequency of CDKN2A promoter
methylation was 43% in 134 invasive cancer cases including 22% of 23
low malignancy patient tumors and 42% of 26 benign cases (Bhagat et
al., 2014). Down-regulation of CDKN2A mRNA expression and hyper-
methylation of the CDKN2A promoter are signiﬁcantly associated.
2.10. Prostate cancer
Prostate cancer presentsmostly as adenocarcinomas and is the second
leading cause of cancer death inmen (Siegel et al., 2015). Silencing of the
CDKN2A gene plays a critical role in prostate cancer progression. Methyl-
ation of the CDKN2A promoter has been reported to occur in 47.6% of 21
patients with poor prognosis (Ameri et al., 2011). Epigenetically, ANRIL
and H3K2me are involved and alternatively bind with CBX7 of PRC1,
thereby repressing CDKN2A gene transcription (Yap et al., 2010).
2.11. Renal cell carcinoma
Accumulation of various genetic aberrations, including the CDKN2A
gene, underlies the development of renal cell carcinomas (Dulaimi et al.,
2004). Evaluation of the methylation status of the promoter CpG island
of CDKN2A and immunohistochemical detection of the p16INK4a-encodedTable 2
Genes and factors correlated with changes in CDKN2A.
Genes/Factors Cancer types Note
HPV Head and neck squamous cell carcinoma CDKN2A alte
EGFR
Lung adenocarcinoma
CDKN2A hom
mutation
KRAS
Hypermethy
mutation
hMLH1 (human mutL homolog
1)
Colorectal cancer (microsatellite
instability)
Hypermethy
SETDB1 (Sporadic cutaneous) Melanoma
Cytoplasmic
with higher
NRAS Cutaneous melanoma
NRAS-mutat
12/23)
SNF5 –
Inactivation
SNF5protein in 57 patients with renal carcinomas revealed that the CDKN2A
gene was hyper-methylated in 22.9% of patients and none of them
expressed the p16INK4a protein product (Vidaurreta et al., 2008). The
lack of p16INK4a protein expression was detected in 52.9% of the tumors,
suggesting the involvement of another genetic alteration or post-tran-
scriptional modiﬁcation of the protein (Vidaurreta et al., 2008).
3. Molecular switches associated with p16INK4a aberrations
The inactivation of CDKN2A in cancer is neither an isolated event nor
does it appear to have a direct link with carcinogen exposure (Table 2).
Analysis of the current literature reveals that promoter methylation of
CDKN2A is not associated with HPV infection, which is a cause of head
and neck squamous cell carcinomas (Chung et al., 2015). However, the
epigenetic changes in CDKN2A are associatedwith simultaneous genetic
or epigenetic alterations in other cancer-related oncogenes or tumor
suppressor genes (Veganzones et al., 2015; Chung et al., 2015; Kostaki
et al., 2014; Tam et al., 2013; Wilson et al., 2010; Jonsson et al., 2010).
Thus, the study of the concordance between p16INK4a inactivation with
other tumor-related genetic/epigenetic lesions could provide new ave-
nues for developing anticancer therapies. Tam et al. have demonstrated
that mutations of the epidermal growth factor receptor (EGFR) and KRAS
are major oncogenic drivers in the pathogenesis of lung adenocarci-
nomas. Themutation of EGFR is reportedly associated with CDKN2A ho-
mozygous deletion or mutation, whereas KRAS mutation is related to
hyper-methylation of the CDKN2A promoter (Tam et al., 2013). Howev-
er, changes in STK11 (also known as LKB1), a gene frequentlymutated in
lung adenocarcinomas, have no impact on CDKN2A inactivationmecha-
nisms (Tam et al., 2013). Veganzones and colleagues investigated the
frequency of simultaneous methylation of CDKN2A and hMLH1, a gene
that encodes a DNA repair enzyme, in colorectal cancer patients with
microsatellite instability (MSI) (Veganzones et al., 2015). The outcome
of the analysis of 51 samples of MSI-positive sporadic colorectal cancer
was expressed by a newvariable referred to as combinedmethylation of
CDKN2A and hMLH1 (CMETH2). Results indicated that 17 of 51 patients
(33.3%) tested positive for CMETH2 expression, which was associated
with poorly differentiated tumors in proximal locations. The clinic-
pathological implication of CMETH2was reﬂected in the overall survival
of patients with distal tumors (Veganzones et al., 2015).
Histone modiﬁcation, especially histone 3-lysine-9 methylation
(H3K9) is a common mechanism of transcriptional repression of gene
expression (Yoruker et al., 2012). SETDB1, which belongs to the family
of SET domain histone methyltransferases including Suv39H, EZH2
andG9a, contains a highly conservedmotif of 150-amino acids and is in-
volved in the modulations of chromatin structure (Yang et al., 2002).
The SETDB1 protein structure contains a CpG DNA methyl-binding do-
main, which regulates H3K9 methylation activity (Ceol et al., 2011).
The CpG island methylation of the CDKN2A gene promoter and expres-
sion of SETDB1 in sporadic cutaneous melanomas are highly correlated
with histologic prognostic parameters (Kostaki et al., 2014).Reference
ration in non-HPV-cancer Chung et al. (2015)
ozygous deletion or mutation is correlated with EGFR
Tam et al. (2013)
lation of CDKN2A promoter is correlated with KRAS
lation of both CDKN2A and hMLH1 is 33.3% (17/51)
Veganzones et al.
(2015)
SETDB1 expression correlates
frequency of CDKN2Amethylation and p16INK4A expression
Kostaki et al. (2014)
ed tumors have CDKN2A promoter methylation (52%,
Jonsson et al. (2010)
of H3K27 tri-methylation of CDKN2A by EZH2 in deﬁcient
Wilson et al. (2010)
35R. Zhao et al. / EBioMedicine 8 (2016) 30–39Methylation of the CDKN2A promoter is associated with 52% (12/23) of
NRAS-mutated cutaneous melanomas compared with BRAF-mutated
(7%, 2/27) tumors (Jonsson et al., 2010). EZH2, a histone methyltrans-
ferase and a catalytic subunit of the PRC2 polycomb repressor, mediates
gene silencing by tri-methylating H3K27 of various target gene pro-
moters (Bracken et al., 2007; Cao et al., 2002). SNF5, one of the core sub-
units of Brahma-associated factor (BAF) chromatin remodeler
complexes, down-regulates EZH2 transcription (Wilson et al., 2010).
Thus, the loss of SNF5 function leads to increased EZH2 expression,
thereby repressing the expression of CDKN2A through the tri-methyla-
tion of H3K27 in the CDKN2A promoter region (Wilson et al., 2010).
4. Epigenetic induction of CDKN2A
Reactivation of silenced CDKN2A or the inhibition of epigenetic re-
pression of the gene could be a rational strategy for the prevention or
treatment of various cancers. While epigenetic silencing of CDKN2A is
caused by DNA hyper-methylation and histone modiﬁcation (Bracken
et al., 2007; Cao et al., 2002; Collado et al., 2007), restoration of
p16INK4a transcriptional activation can be achieved by a set of intracellu-
lar regulatory genes as well as a series of small molecule epigenetic
modiﬁers (Table 3, Figs. 3, 4) (Crea et al., 2009; Feng et al., 2009;
Hassler et al., 2012; Kollmann et al., 2011; Li et al., 2013a; Majid et al.,
2008; Nandakumar et al., 2011; Valdez et al., 2015; Zhang and Tong,
2014).
4.1. Induction of CDKN2A by regulatory genes
The FOXA1 (Forkhead box A1) protein is a transcription factor that
regulates the expression of p16INK4a (Li et al., 2013a; Zhang and Tong,
2014). In hormone-dependent cancers, such as breast and prostate can-
cers, the expression of FOXA1 is positively correlatedwith the expression
of p16INK4a, but inhibits the expression of EZH2, which is a component of
PRC2 and an epigenetic repressor of CDKN2A (Nanni et al., 2006). FOXA1
directly binds to the C-terminal histone-binding motif and inhibits EZH2
methyltransferase activity, thereby inducing the expression of p16INK4a
and suppressing cancer cell growth (Zhang and Tong, 2014).
ZBP-89, a four-zincﬁnger transcription factor, plays a role in the reg-
ulation of target genes by binding to the GC-rich DNA elements (Wu et
al., 2007). ZBP-89 directly recruits histone deacetylase-3 (HDAC3) to
the CDKN2A promoter and represses the expression CDKN2A by histone
hypo-acetylation (Feng et al., 2009). Therefore knockdown of ZBP-89Table 3
Epigenetic induction of p16INKa.
Inducer Mechanisms
Genes
FOXA1 EZH2 inhibition
Si-ZBP-89 HDAC3 inhibition
Jmjd3 Histone demethylation
Mutant UHRF1 H3K9me3 inhibition
c-JUN Protect DNA methylation
Compounds
Genistein
Induction of histone acetyl transferase
Modiﬁcation of histone and Inhibition o
c-MYC to CDKN2A promoter
Sulforaphane (SFN) HDAC3 inhibition by induction of Nrf2
EGCG DNA demethylation and histone acetyl
TSA HBP1 transcription factor acetylation
EGCG and TSA DNA demethylation
TSA and 5-aza-2′-
deoxycytidine
DNA demethylation
5-aza-2′-
deoxycytidine
DNA demethylation
5-aza-2′-
deoxycytidine and irinotecan
DNA demethylation
Cladribine, clofarabine DNA demethylation
Doxorubicin, FUMI (5-ﬂuorouracil
+ mitomycin C)
DNA demethylation(ZBP-89i) by a speciﬁc small interfering RNA vector induced the expres-
sion of p16INK4a and cell senescence in NCI-H460 human lung cancer
cells by promoting histone acetylation (Feng et al., 2009).
Jmjd3 (jumonji domin containing 3) is a histone lysine demethylase,
which especially works to remove the tri-methylation of histone H3 at
lysine 27. Jmjd3 induces expression of p16INK4a and senescence of
Schwann cells under the conditions of nerve regeneration and tumori-
genic stimulation (Gomez-Sanchez et al., 2013). The UHRF1 (ubiqui-
tin-like plant homeobox domain (PHD) and RING ﬁnger containing 1)
protein interacts with DNA methyltransferase 1 (DNMT1) and recog-
nizes hemi-methylated CpG dinucleotides through its SRA (SET- and
RING-associated domain) region (Bostick et al., 2007). The aromatic
cage mutant of tandem tudor domain (TTD, 124–285 aa) within
UHRF1 cannot bind to H2K9me3 and therefore induces the expression
of p16INK4a (Nady et al., 2011).
The c-Jun protein is a component of activator protein (AP)-1 and a
common regulator of cell cycle components and was reported to have
a direct role in regulating gene transcription of e.g., p53 and cyclin D1.
Although JunB, as a tumor enhancer, reportedly inhibits promoter
methylation of Cdk6 in BCR-ABL-induced leukemia (Ott et al., 2007),
binding of c-Jun to the promoter region shows a protective function
and preventsmethylation and silencing of these genes. Because the pro-
moter region of the CDKN2A gene includes binding sites for AP-1, c-Jun
can inhibitmethylation of the CDKN2Apromoter (Kollmannet al., 2011)
4.2. Induction of p16INK4a by reagents
A number of natural and synthetic small molecule modiﬁers of epi-
genetic regulation of gene expression have been identiﬁed (Fig. 4).
Many of these small molecules are capable of restoring the expression
of p16INK4a in various cancers. Genistein, an isoﬂavone present in soy-
bean, is a cancer chemopreventive agent that inhibits cell proliferation
and induces apoptosis (Gullett et al., 2010). Li et al. reported that genis-
tein represses early breast tumorigenesis through epigenetic regulation
of CDKN2A by impacting histone modiﬁcations as well as by recruiting
the BMI1-c-MYC complex to the regulatory region in the CDKN2A pro-
moter (Li et al., 2013b). In prostate cancer, treatment with genistein in-
creased acetylated histones 3 and 4 of the CDKN2A transcription start
sites (Majid et al., 2008). Thus, soybean products containing genistein
might be useful in preventing breast and prostate cancer through tran-
scriptional activation of CDKN2A by modulating its epigenetic silencing
(Li et al., 2013b; Majid et al., 2008). Sulforaphane, a major componentCancer types References
Breast cancer and prostate
cancer
Zhang and Tong (2014), Li
et al. (2013a)
NCI-460 human lung cancer cells Feng et al. (2009)
Neuroﬁbroma Schwann cells
(Gomez-Sanchez et al.
(2013)
Nady et al. (2011)
Kollmann et al. (2011)
(HAT) Prostate cancer Majid et al. (2008)
f binding BMI1 and
Breast cancer Li et al. (2013b)
Colon cancer Rajendran et al. (2015)
ation Skin cancer cell Nandakumar et al. (2011)
Wang et al.1 (2012)
Lymphoma Wu et al. (2013)
Epstein–Barr virus-associated
gastric cancer cells
He et al. (2015)
Large cell lymphoma Hassler et al. (2012)
Colorectal cancer cells Crea et al., (2009)
Acute myeloid leukemia Valdez et al. (2015)
Breast cancer Klajic et al. (2014)
Fig. 3. The epigenetic induction of p16INK4a by regulatory genes. FOXA1, Si-ZBP-89, Jmjd3, Mutant UHRF1 and c-JUN induce p16INK4a protein expression by re-activation of the CDKN2A
promoter.
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tor erythroid 2 (NF-E2)-related factor 2 (Nrf2), which regulates the
transcriptional activation of a battery of genes encoding various phase
2 detoxiﬁcation enzymes (Fahey et al., 1997; Kensler et al., 2013).
Rajendran et al. reported that Nrf2wildtype mice showed a higher inci-
dence of colon tumors than Nrf2 heterozygous (Nrf2+/−) mice when
treatedwith 1,2-dimethylhydrazine. Tumors fromwildtypemice exhib-
ited higher HDAC3 levels globally and deregulated p16INK4a levels local-
ly. Treatmentwith sulforaphanemarkedly reduced the tumor burden in
wildtype mice but not in Nrf2+/− mice. Sulforaphane, an inhibitor of
HDAC3, a repressor of p16INK4a, induced p16INK4a expression and re-
duced the tumor burden in this model (Rajendran et al., 2015).Fig. 4. The epigenetic induction of p16INK4a by reagents. Phytochemicals such as genistein, SF
clofarabine, doxorubicin, FUMI (5-ﬂuorouracil + mitomycin C) and combinations reactivate pEpigallocatechin-3-gallate (EGCG), amain polyphenol component of
green tea, stimulated expression of p16INK4a by inhibiting DNA methyl-
ation and increasing histone acetylation in the CDKN2A promoter of
human skin cancer cells (Nandakumar et al., 2011). Trichostatin A
(TSA) is an HDAC4 inhibitor that elevated the acetylation of HBP1
(K419), a member homologous to the sequence-speciﬁc high mobility
group (HMG) family of transcription factors, and increased the expres-
sion of p16INK4a, thereby inducing apoptosis and differentiation (Wang
et al., 2012). The combination treatment with inhibitors of DNMTs and
HDACs might be a representative therapeutic strategy in cancer. Treat-
ment of CA46 lymphoma cellswith EGCG (24 μg/ml) or the combination
treatment of EGCG (6 μg/ml) and TSA (15 ng/ml) resulted in lowerN and EGCG and synthetic chemicals, TSA, 5-aza-2′-deoxycytidine, irinotecan, cladribine,
16INK4a protein expression by prohibiting alterations in the CDKN2A promoter.
37R. Zhao et al. / EBioMedicine 8 (2016) 30–39proliferative indices when compared to the other groups. Co-treatment
with EGCG and TSA decreased the DNA methylation of CDKN2A, which
coincided with increased CDKN2AmRNA and protein expression. Thus,
EGCG and TSA synergistically induced CDKN2A expression by reducing
promotermethylation, whichmight decrease CA46 lymphoma cell pro-
liferation (Wu et al., 2013).
5-Aza-2′-dexoycytidine (5-aza-CdR, decitabine, Dacogen®) is a
DNMT inhibitor, which has been approved by the Food and Drug Ad-
ministration (FDA) for the treatment of myelodysplastic syndrome, a
hematological malignancy (Scandura et al., 2011). Treatment of ana-
plastic large cell lymphoma cells with 5-aza-CdR resulted in the inhibi-
tion of proliferation throughG1phase cell cycle arrest in vitro and in vivo
through re-expression of p16INK4a (Hassler et al., 2012). Furthermore,
combination treatment with TSA and 5-aza-CdR exerted synergic cell
growth inhibition and apoptosis in EBV-associated gastric carcinoma
through the induction of CDKN2A by inhibiting methylation (He et al.,
2015). On the other hand, co-treatment with 5-aza-CdR and irinotecan,
a topoisomerase-1 inhibitor, caused a more sensitive cytotoxic effect in
p53-mutated colon cancer cells, such as HT-29, SW620, and WiDr cells
(Crea et al., 2009). The synergistic effect of 5-aza-CdR and irinotecan
was signiﬁcantly associated with topoisomerase I up-regulation by 5-
aza-CdR, and combined to induce CDKN2A expression through promot-
er demethylation as well as Sp1 up-regulation. Expression of p16INK4a
enhanced cell cycle arrest after irinotecan treatment (Crea et al., 2009).
Cladribine and clofarabine are second-generation analogues of 2′-
deoxyadenosine. Fludarabine (Fludara) and Busulfan (Myeran) and
are cell cycle non-speciﬁc alkylating antineoplastic agents. Although
both cladribine and clofarabine induced p16INK4a expression, cladribine
was effective at a lower concentration compared to clofarabine (Valdez
et al., 2015). The combination of cladribine or clofarabine with
ﬂudarabin and busulfan caused synergic cytotoxicity in acute myeloid
leukemia. Moreover, the addition of panobinostat, an HDAC inhibitor,
and 5-aza-CdR with these combinations also enhanced cytotoxicity. In-
clusion of panobiostat and 5-aza-CdR increased histone modiﬁcations
and DNA demethylation, and increased the levels of the p16INK4a,
p15INK4b and p21Waf1/Cip1 proteins (Valdez et al., 2015).
Treatment with doxorubicin and FUMI (5-ﬂuorouracil and mitomy-
cin C) in breast cancer resulted in demethylation of the CDKN2A pro-
moter by 19.3% and 9.1%, respectively (Klajic et al., 2014). The CDKN2A
genewas differentially methylated before/after treatmentwith doxoru-
bicin and before/after treatment between responders. Lower levels of
methylation were observed after treatment in the responder groups.
Also, CDKN2Amethylation levels among the non-responders were sig-
niﬁcantly changed (Klajic et al., 2014).
5. Conclusion
A high frequency of genetic and epigenetic alterations (e.g., promot-
er hyper-methylation, homozygous deletion or mutation) in the
CDKN2A gene has been observed in human cancer cell lines derived
from various tumor types. However, a signiﬁcantly lower frequency of
CDKN2A abnormalities has been reported in fresh, non-cultured prima-
ry tumors and cell lines. Therefore, regulation of CDKN2A abnormalities
will have beneﬁts for the cancer prevention and/or therapy.
Outstanding questions
Besides genetic and epigenetic aberrations, the regulation of gene
expression is also associated with the status of many other proteins,
such as p53, BRAF, ataxia talengectia mutated (ATM), phosphatase
and tensin homolog deleted at chromosome10 (PTEN), KRAS and phos-
phatidylinositol 3-kinase (PI3-K) as well as the components of the
CDKN2A promoter, such as the PRC1 and PRC2 complexes and long non-
coding RNAs. HPV, a small DNA virus (major types HPV-16 andHPV-18)
expresses E6 and E7 oncoproteins and is linked causally tomost cervical
cancers that show a high expression of p16INK4a (Kobalka et al., 2015;Munger et al., 2013; Pauck et al., 2014; Nehls et al., 2008). The E6 and
E7 oncoproteins directly blockp53 and pRb tumor suppressors resulting
in the accumulation of p16INK4a, which is upstream of p53 and pRb
(Dyson et al., 1989; Scheffner et al., 1993). HPV-infection-associated
cervical cancer also mediates the high expression of p16INK4a by epige-
netic modulation of the CDKN2A upstream promoter (Nehls et al.,
2008; McLaughlin-Drubin et al., 2013). Thus in HPV-infection-associat-
ed cancer, we should consider the p16INK4a as a biomarker in an oppo-
site manner than what is generally expected. Although smoking and/
or drinking is a risk factor for lung, head and neck, and pancreatic can-
cers (Gillison et al., 2012; Jiao et al., 2007; Tam et al., 2013), meaningful
correlations of p16INK4a expressionwith smoking or drinking are not yet
supported by strong evidence (Jiao et al., 2007; Gillison et al., 2012; Tam
et al., 2013). Because p16INK4a is a critical regulator of cell proliferation
and is inactivated during the course of tumorigenesis, methods for res-
toration of p16INK4a function could provide good therapeutic strategies.
To achieve this goal, the focus has been directed toward understanding
the molecular mechanisms, especially genetic and epigenetic changes
that lead to p16INK4a inactivation in cancer, and developing small mole-
cule modiﬁers of these mechanistic switches. For example, ZBP-89 can
induce the expression of p16INK4a (Zhang et al., 2010). Likewise,
FOXA1 and jmjd3 enhance CDKN2A expression by direct transcriptional
activation andpromoter di-methylation, respectively. Thus, discovery of
small molecule activators of ZBP-89, jmjd3 or FOXA1 might be a future
research goal for developing novel anticancer therapies. On the other
hand, factors that repress CDKN2A gene expression, such as SETDB1,
EZH2, or PcB proteins, could be potential therapeutic targets to induce
p16INK4a functionality and tumor suppression. Although several natural
and synthetic compounds, such as genistein, sulforaphane, EGCG and 5-
aza-CdR have been shown to intervene against the epigenetic silencing
of CDKN2A, mechanism-based development of p16INK4a activators war-
rants further studies.
Search strategy and selection criteria
This review was prepared by searching in PubMed with querying
key words: p16INK4a, epigenetics, alteration, gene alteration, gene si-
lencing, cancer, promoter alteration and induction of p16INK4a. The
search was conducted for research articles including clinical reports
up to 28 December 2015 and we especially summarized research arti-
cles in each cancer type.
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